Literature DB >> 33369951

Consumption of meat containing ractopamine might enhance tumor growth through induction of asparagine synthetase.

Frank S Fan1.   

Abstract

There is currently no evidence of the carcinogenic effect of the β-adrenergic agonist ractopamine added in finishing swine and cattle feed for promoting leanness. Nonetheless, it has the capability of stimulating expression of asparagine synthetase (ASNS) through activating transcription factor 5, and many other genes involved in the stress reaction in the skeletal muscle of pigs according to published scientific articles. Because overexpression of ASNS has been detected as a key player in amino acid response and unfolded protein response during the development of not a few malignant diseases, especially those with KRAS mutations, and found to be closely related to tumor proliferation, invasion and metastasis, it seems reasonable to hypothesize that intake of ractopamine residue in meat might bring negative effects to cancer patients.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33369951      PMCID: PMC8638813          DOI: 10.1097/CEJ.0000000000000655

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.164


Introduction

Ractopamine, classified as a β-adrenergic agonist, has been used to increase carcass lean percentage and growth rate by pork and beef producers in the USA in the past two decades. Although its use has obtained approval as a feed additive for swine in the USA, Canada, Mexico and Brazil, ractopamine is prohibited in the European Union, China and many other countries (Vezzoni de Almeida ). Despite the potential contribution of ractopamine to environmental protection by increasing efficiency of husbandry, shortening finishing swine growth period, decreasing feed need and thus reducing the amount of water, fertilizer and pesticide for crop cultivation (Woods ), people inevitably are still worried about the safety of ractopamine residue in meat especially in those countries where pork is imported from the USA. In addition to the health risk of cardiovascular functional disorders and cardiovascular diseases which might lead to life expectancy decrease (Zaitseva ), another major concern is whether ractopamine will promote malignancy formation. Even with the promise that genotoxicity and carcinogenicity could be excluded with acceptable daily intakes on recommended maximal residue limits of ractopamine in animal food except for a dose-dependent slightly increased incidence of uterine leiomyoma in rat studies (Joint FAO/WHO Expert Committee on Food Additives 2004; Scientific Opinion of the Panel on Additives and Products or Substances used in Animal Feed 2009), what’s the effect of ractopamine on cancer already existing remains a question to be carefully investigated. Herein, a hypothesis is raised that ractopamine might stimulate tumor growth through induction of asparagine synthetase (ASNS) expression.

Metabolic reprogramming in cancer cells

During tumorigenesis and metastasis, being affected by oncogene activation and tumor suppressor inactivation, cancer cells rewire their metabolism to meet the biosynthetic demands of high proliferation rates and achieve a new state of homeostasis, losing expression of some anabolic genes and becoming eagerly dependent on certain specific amino acids which could be deprived by enzymes designed as therapeutic modalities (Maggi and Scotti, 2019; Garcia-Bermudez ). Nevertheless, cancer cells could also manage to start initially silent genes in response to the urgency of producing amino acids they need. It has been disclosed that one of these genes activated in cell stress is ASNS.

Asparagine synthetase in tumor biology

ASNS produces asparagine from aspartate in an ATP-dependent process during which glutamine is converted to glutamate at the same time (Lomelino ). The basal expression of ASNS is generally low in mammalian organs except in the pancreas and testes as shown in rat experiments and human studies. Nonetheless, transcription of the gene for ASNS could be turned on under stress conditions, such as amino acid response and unfolded protein response through activating transcription factor 4 (ATF4) (Balasubramanian ). For example, clinical investigation has revealed that ASNS expression is much increased in the early stage of development of hepatocellular carcinoma as compared with normal liver tissue (Zhang ). In tumors with KRAS mutations, such as a portion of colon and nonsmall cell lung cancer, activation of ASNS gene seems to be a characteristic presentation (Toda ; Gwinn ). Furthermore, asparagine was found to be the key determinant factor governing metastasis potential of breast cancer in a human case. Altering asparagine availability in vitro, for example, knockdown of the ASNS gene, strongly influenced the invasive capability of breast cancer cells (Knott ). Most importantly, extraordinary asparagine dependence was ascertained in mouse soft-tissue sarcoma generated by oncogenic KRAS and disruption of Cdkn2a. Silencing of the ASNS gene in both mouse and human sarcoma cell lines led to reduction of the percentage of S phase cells (Hettmer ).

Ractopamine increases asparagine synthetase in skeletal muscles

In a recently published study, skeletal muscle transcriptome analysis in pigs administrated with ractopamine (20 ppm in feed) disclosed remarkably increased gene expressions of ASNS and activating transcription factor 5 (ATF5) but not ATF4 in comparison with pigs injected with growth hormone Reporcin and pigs on ordinary feed (Brown ). On the other hand, the expression of over 20 ATF4 target genes was induced by ractopamine. The authors concluded that ractopamine treatment resulted in an integrated stress response, peculiarly genes linked to amino acid biosynthesis and protein translation, in the skeletal muscle of pigs.

Hypothesis

Based on its nature as a β-adrenergic agonist, ractopamine surely acts on organs other than skeletal muscle as well. For patients who have malignant diseases including at least hepatocellular carcinoma, breast cancer, soft-tissue sarcoma, colon cancer and nonsmall cell lung cancer, particularly KRAS-mutated as mentioned above, consumption of meat containing ractopamine presumably will trigger expression of ASNS and other genes involved in integrated stress response and facilitate tumor growth or metastasis. The induction of ATF5 in the skeletal muscle of pigs provides an alternative pathway of stress response in addition to the well-known ATF4 one. Confirmation of this speculation awaits delicate laboratory investigation, clinical trials and long-term epidemiologic observation but the risk should not be ignored.

Discussion and conclusion

Deprivation of asparagine with bacterial l-asparaginase has been adopted for the treatment of acute lymphoblastic leukemia (ALL) for four decades, taking advantage of the lack of ASNS expression in most ALL. Extension of l-asparaginase use to other malignancies has always been an attractive idea to clinicians as well. However, the main concern would be the correlation of l-asparaginase sensitivity with cellular ASNS content as seen in the studies of ALL, ovarian cancer and NK/T cell lymphoma (Su ; Lorenzi and Weinstein 2009; Li ). If ractopamine does stimulate ASNS expression, the strategy of l-asparaginase would be badly hindered in cancer patients who used to consume meat containing ractopamine. Finally, recent research discovered that besides its canonical role of protein synthesis, asparagine may have additional functions in the regulation of cellular growth, prompting reconsideration of the importance of ASNS in cancer therapy (Chiu et al., 2020). Accordingly, the presumed negative effects of ractopamine on cancer progression probably will soon become a novel focus of oncology research in the near future.

Acknowledgements

Conflicts of interest There are no conflicts of interest.
  14 in total

1.  Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase.

Authors:  Dana M Gwinn; Alex G Lee; Marcela Briones-Martin-Del-Campo; Crystal S Conn; David R Simpson; Anna I Scott; Anthony Le; Tina M Cowan; Davide Ruggero; E Alejandro Sweet-Cordero
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

Review 2.  Asparagine synthetase: Function, structure, and role in disease.

Authors:  Carrie L Lomelino; Jacob T Andring; Robert McKenna; Michael S Kilberg
Journal:  J Biol Chem       Date:  2017-10-30       Impact factor: 5.157

3.  Evaluation of certain veterinary drug residues in food. Sixty-second report of the Joint FAO/WHO Expert Committee on food additives.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2004

Review 4.  Asparagine synthetase: regulation by cell stress and involvement in tumor biology.

Authors:  Mukundh N Balasubramanian; Elizabeth A Butterworth; Michael S Kilberg
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-12       Impact factor: 4.310

5.  Asparagine bioavailability governs metastasis in a model of breast cancer.

Authors:  Simon R V Knott; Elvin Wagenblast; Showkhin Khan; Sun Y Kim; Mar Soto; Michel Wagner; Marc-Olivier Turgeon; Lisa Fish; Nicolas Erard; Annika L Gable; Ashley R Maceli; Steffen Dickopf; Evangelia K Papachristou; Clive S D'Santos; Lisa A Carey; John E Wilkinson; J Chuck Harrell; Charles M Perou; Hani Goodarzi; George Poulogiannis; Gregory J Hannon
Journal:  Nature       Date:  2018-02-07       Impact factor: 49.962

Review 6.  Targeting extracellular nutrient dependencies of cancer cells.

Authors:  Javier Garcia-Bermudez; Robert T Williams; Rohiverth Guarecuco; Kıvanç Birsoy
Journal:  Mol Metab       Date:  2019-11-23       Impact factor: 7.422

Review 7.  Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia.

Authors:  Martina Chiu; Giuseppe Taurino; Massimiliano G Bianchi; Michael S Kilberg; Ovidio Bussolati
Journal:  Front Oncol       Date:  2020-01-09       Impact factor: 6.244

8.  Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma.

Authors:  B Zhang; L-W Dong; Y-X Tan; J Zhang; Y-F Pan; C Yang; M-H Li; Z-W Ding; L-J Liu; T-Y Jiang; J-H Yang; H-Y Wang
Journal:  Br J Cancer       Date:  2013-06-13       Impact factor: 7.640

9.  Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma.

Authors:  Simone Hettmer; Anna C Schinzel; Daria Tchessalova; Michaela Schneider; Christina L Parker; Roderick T Bronson; Nigel Gj Richards; William C Hahn; Amy J Wagers
Journal:  Elife       Date:  2015-10-24       Impact factor: 8.140

10.  The Beta-adrenergic agonist, Ractopamine, increases skeletal muscle expression of Asparagine Synthetase as part of an integrated stress response gene program.

Authors:  David Brown; Kevin Ryan; Zoe Daniel; Molebeledi Mareko; Richard Talbot; Joanna Moreton; Tom C B Giles; Richard Emes; Charlie Hodgman; Tim Parr; John M Brameld
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379

View more
  1 in total

Review 1.  Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review.

Authors:  Xinyi Shen; Abhishek Jain; Oladimeji Aladelokun; Hong Yan; Austin Gilbride; Leah M Ferrucci; Lingeng Lu; Sajid A Khan; Caroline H Johnson
Journal:  Front Mol Biosci       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.